Gilead Sciences's most recent trend suggests a bullish bias. One trading opportunity on Gilead Sciences is a Bull Put Spread using a strike $80.00 short put and a strike $75.00 long put offers a potential 14.42% return on risk over the next 35 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $80.00 by expiration. The full premium credit of $0.63 would be kept by the premium seller. The risk of $4.37 would be incurred if the stock dropped below the $75.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Gilead Sciences is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)
Wed, 13 Sep 2017 19:05:00 +0000
Kite is a good buy, but this investment will have a bigger short-term effect.
Gilead Sciences, Inc. :GILD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
Wed, 13 Sep 2017 15:44:06 +0000
Categories: Yahoo FinanceGet free summary analysis Gilead Sciences, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Gilead Sciences, Inc. – Amgen Inc., Vertex Pharmaceuticals Incorporated, Celgene Corporation, Alexion Pharmaceuticals, Inc., AbbVie, Inc., Illumina, Inc., Biogen Inc., Eli Lilly and Company, Merck & Co., Inc. … Read more
Gilead: Too Early for Kite Credit?
Wed, 13 Sep 2017 14:12:00 +0000
Gilead Sciences (GILD) finally did what investors had hoped it would do–make a deal. Investors sure seem to like Gilead's acquisition of Kite Pharma (KITE). Its shares have gained 16% during the past month, outpacing the iShares Nasdaq Biotechnology ETF's (IBB) 9% rise during the same period.
Short Sellers Hike Bets in Major Biotechs
Wed, 13 Sep 2017 12:55:07 +0000
The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Must-Know Recent Developments for Gilead
Wed, 13 Sep 2017 11:37:21 +0000
On August 28, 2017, Gilead Sciences entered a definitive agreement to acquire Kite Pharma (KITE) for $180 per share in cash.
Also on Market Tamer…
Follow Us on Facebook